Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
9 Results for "
human cervical cancer cell lines
" in MedChemExpress (MCE) Product Catalog:
Products (9)
9 Results for "human cervical cancer cell lines" in MCE Product Catalog:
Cat. No.: HY-178960
Target:
Research Areas:
Tubulin-IN-59 (Compound 8g) is an orally active Tubulin inhibitor. Tubulin-IN-59 exhibits potent anti-proliferative activity against HCT116 colorectal cancer, HeLa cervical cancer, and HepG2 liver cancer cell lines, with its IC₅₀ value ranging from 16 to 35 nM. Tubulin-IN-59 arrests HeLa cells in the G2/M phase and induces cell apoptosis. Tubulin-IN-59 demonstrates significant anti-tumor activity in the HT29 human colon cancer mouse xenograft model. Tubulin-IN-59 can be used for the study of colorectal cancer and cervical cancer .
Cat. No.: HY-121352
CAS No.: 934464-79-6
Target:
Research Areas:
Kibdelone C is a hexacyclic tetrahydroxanthone natural product and anticancer agent with sub-nanomolar GI50 activity against human SR leukemia and SN12C renal carcinoma cell lines. Kibdelone C disrupts the actin cytoskeleton in human cancer cells, leading to cell contraction and actin stress fiber formation, without direct actin binding, actin polymerization effects, topoisomerase I/II inhibition, or DNA binding. Kibdelone C can be used for the research of leukemia, and renal cell carcinoma .
Cat. No.: HY-126743
CAS No.: 1219095-76-7
Target:
Research Areas:
JBIR-22 is a protein-protein interaction inhibitor of proteasome assembly factor 3 homodimer, which has the activity of inhibiting this interaction and exerting long-term cytotoxicity against human cervical cancer cell lines, and its stereochemical structure has been determined by total synthesis.
Cat. No.: HY-N7350
CAS No.: 2055155-75-2
Category:
Target:
Cat. No.: HY-181947
Research Areas:
IDO1-IN-33 (Compound YC-16) is a IDO1 inhibitor (with an IC50 of 0.18 μM for IDO1 in HeLa cells). IDO1-IN-33 acts as an apo-IDO1 inhibitor by slowly and competitively displacing heme from mature holo-IDO1 and rapidly binding to the heme-binding site of immature apo-IDO1, without altering the expression level of IDO1. IDO1-IN-33 can be used for the research of hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, and cervical cancer .
Cat. No.: HY-111015
CAS No.: 955082-09-4
Target:
Research Areas:
IRC-083927 hydrochloride is an orally active tubulin inhibitor. IRC-083927 hydrochloride binds competitively to the colchicine-binding site on tubulin, inhibits tubulin polymerization, disrupts the microtubule cytoskeleton, and arrests the cell cycle at the G2-M phase. IRC-083927 hydrochloride can be used in research related to human cervical cancer, hormone-independent breast cancer, pancreatic cancer, prostate cancer, and small cell lung cancer .
Cat. No.: HY-111015A
CAS No.: 955157-23-0
Target:
Research Areas:
IRC-083927 is an orally active tubulin inhibitor. IRC-083927 binds competitively to the colchicine-binding site on tubulin, inhibits tubulin polymerization, disrupts the microtubule cytoskeleton, and arrests the cell cycle at the G2-M phase. IRC-083927 can be used in research related to human cervical cancer, hormone-independent breast cancer, pancreatic cancer, prostate cancer, and small cell lung cancer .
Cat. No.: HY-D3182
CAS No.: 2252329-12-5
Cat. No.: HY-N17533
CAS No.: 1868129-15-0
Target:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
